OncoTalks | Oncology Insights at Your Fingertips

In this episode of OncoTalks, host Dr. Ira Zackon welcomes Dr. Brad Christensen to discuss how mature clinical trial data are influencing treatment selection and patient management in CLL. Together, they explore the importance of long-term disease control, tolerability and safety considerations, and the factors that guide decisions between continuous and time-limited treatment approaches. The conv...

Adherence starts long before the first missed dose. In this episode, Dr. Brad Christensen shares real-world insights on helping patients with chronic lymphocytic leukemia (CLL) stay on BTK inhibitor therapy over the long term. Topics include individualized treatment selection, the role of dosing flexibility in real-world practice, and proactive adverse event management. Dr. Christensen also highli...

In the final installment, Dr. Luke Fletcher shares strategies for managing resistant chronic myeloid leukemia (CML), including adverse event monitoring, supportive care, and response-based dose optimization to improve long-term treatment success. This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance. Deve...

Dr. Luke Fletcher discusses mutation testing in chronic myeloid leukemia (CML), including when to test, how results influence treatment decisions, and the clinical significance of mutations such as T315I. This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical Guide to Treatment, Monitoring, and Resistance. Developed and produced by Ontada Learn. The co...

Dr. Luke Fletcher examines the growing role of measurable residual disease (MRD) and molecular response in treatment monitoring, and the impact of tyrosine kinase inhibitor (TKI) selection on achieving deep and durable responses for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL...

Dr. Luke Fletcher reviews the evolving treatment approach for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), highlighting how tyrosine kinase inhibitors (TKIs) are integrated throughout induction, consolidation, and maintenance therapy to support long-term disease control. This episode is part of the micro-series, Navigating TKI Therapy Across Ph+ ALL and CML: A Practical...

Dr. Edward Pearson explores the latest advancement in anti-CD38 therapy: subcutaneous delivery of isatuximab via on-body injector. He reviews clinical evidence on efficacy, safety, and patient preference, and shares how he anticipates this innovation to impact clinic workflows, care teams, and the overall multiple myeloma patient experience. This episode is part of the micro-series, Optimizing Car...

Brook Cox, BSN, RN, OCN, an oncology nurse and infusion room supervisor, shares how subcutaneous administration of anti-CD38 therapy has transformed infusion center operations, improved patient flow, and created both opportunities and challenges for nursing teams caring for patients with multiple myeloma. This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives o...

Dr. Edward Pearson reviews pivotal clinical trial data supporting anti-CD38-based regimens and explores how clinicians can balance efficacy, tolerability, and quality of life when managing high-risk and transplant-ineligible multiple myeloma. This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation. Developed and produced by O...

Dr. Edward Pearson discusses the growing role of anti-CD38-based quadruplet therapy and key considerations influencing frontline therapy selection for patients with newly diagnosed, transplant-ineligible multiple myeloma. This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation. Developed and produced by Ontada Learn. The cont...

This learning module provides a brief overview of HER2 testing in metastatic non-small cell lung, bladder, rectal, cervical, biliary tract, ovarian, pancreatic, endometrial, and colon cancers, highlighting disease-specific testing approaches, interpretation of HER2 results, and key dosing and safety monitoring considerations. Developed and produced by Ontada Learn. The content is intended for educ...

In this episode of OncoTalks, Dr. Yair Levy shares his approach to BTKi selection for patients with chronic lymphocytic leukemia (CLL), highlighting the growing role of second-generation BTK inhibitors, and the importance of tailoring treatment to individual patient characteristics. The discussion also explores the challenges providers face when navigating insurance requirements, medication access...

In this episode of OncoTalks, host Tulsi Patel is joined by Dr. Yair Levy to discuss the growing impact of utilization management policies on chronic lymphocytic leukemia (CLL) care. As treatment options expand, personalized therapy selection is more critical than ever, yet step therapy requirements and payer restrictions are increasingly shaping clinical decisions. Dr. Levy shares real-world insi...

Follow the clinical journey of extrapulmonary neuroendocrine carcinoma (EP-NEC) through a real-world patient case presented by Dr. Deepak Bhamidipati. This episode explores key diagnostic considerations, gaps in current treatment, and the need for more durable therapeutic options. Learn how emerging DLL3-targeted therapies, including the DLL3/CD3 T-cell engager, obrixtamig, are showing promise in...

Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispecific T‑cell engagers. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended f...

With limited durable options available, new approaches are urgently needed in EP-NEC. This episode highlights emerging therapies, including immunotherapy‑based strategies and early clinical trial data shaping future treatment directions. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Learn. The content is intended for e...

Explore the current EP‑NEC treatment landscape, from first‑line platinum‑based therapy and etoposide to second‑line challenges. Dr. Pelster reviews guideline‑recommended options, sequencing considerations, and why clinical trials are essential in this aggressive disease. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Developed and produced by Ontada Le...

Dr. Meredith Pelster introduces extrapulmonary neuroendocrine carcinoma (EP‑NEC), outlining how patients present and what distinguishes this rare disease. Learn the key elements of diagnostic workup, including pathology, imaging, and features that differentiate EP‑NEC from other neuroendocrine tumors. This episode is part of the Micro-Series, EP-NEC Explained: Diagnosis to Emerging Therapies. Deve...

In this episode of OncoTalks, host Tulsi Patel speaks with Brandon Dyson, PharmD, BCOP, BCPS, Director of Pharmacy Education at Texas Oncology, about how the Maximum Fair Price (MFP) program may influence prostate cancer care in community oncology. They review therapies selected for MFP regulation, key implementation timelines, and share practical steps oncology providers and practices can take no...

In this episode of OncoTalks, host Tulsi Patel speaks with Dr. Hope Rugo about the evolving role of antibody‑drug conjugates (ADCs) in breast cancer, with a focus on sacituzumab govitecan, the first and currently only approved ADC for patients with previously treated metastatic triple‑negative breast cancer (mTNBC). Dr. Rugo highlights key clinical data supporting its approvals in mTNBC and HR‑pos...

In this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing variability in testing practices and emphasize the importance of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Tune in to review the latest...

In the final episode of this four-part series, Dr. Mohit Narang looks ahead to emerging innovations in multiple myeloma. Learn about new therapeutic targets, MRD testing, sequencing strategies, and personalized approaches that aim to optimize outcomes and bring us closer to functional cures. This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Inn...

In part three of four, Dr. Mohit Narang explores how bispecific antibodies and other advanced treatments are being implemented in real-world community oncology practices. Discover the operational challenges, safety considerations, and strategies that enable community oncology centers to expand access to these transformative therapies for the broader patient population. This episode is part of the...

In part two of four, Dr. Mohit Narang examines the rapidly evolving treatment landscape for multiple myeloma. Tune in to learn how therapy has progressed from doublets to quadruplets, reshaping the role of autologous stem cell transplant, and the impact of the latest immune therapies, including monoclonal antibodies, bispecific antibody therapy, and CAR-T approaches. This episode is part of the Mi...

In part one of four, Dr. Mohit Narang from Maryland Oncology Hematology provides a foundational overview of multiple myeloma.  Tune in to learn how its incidence has evolved over the past thirty years, what we know today about disease risk factors, and the molecular mechanisms underlying multiple myeloma pathophysiology and diagnosis.  This episode is part of the Micro-Series, Multiple Myeloma in...